Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by JPMorgan Chase & Co. from a “neutral” rating to an ...

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

Fintel reports that on March 24, 2025, JP Morgan upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from ...

CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.

Cardiology drug and device makers will be back in the spotlight this weekend as the annual scientific meeting of the American ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has earned a consensus rating of “Moderate Buy” from the twenty ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

JPMorgan upgraded Alnylam (ALNY) to Overweight from Neutral with a price target of $328, up from $280. The firm increased TTR silencer ...

Cantor Fitzgerald said that while the firm “congratulates” Alnylam Pharmaceuticals (ALNY) on last week’s Amvuttra approval, with the stock ...